YouSigma- the web's most extensive resource for information
$6.99 Domain Names at Network Solutions®!
Astrazeneca PLC (SWOT Analysis)

Go to Home Page

Tell your friend about this WebSite!

Download PDF Version!

“SWOT is an acronym for the internal Strengths and Weaknesses of a firm and the environmental Opportunities and Threats facing that firm. SWOT analysis is a widely used technique through which managers create a quick overview of a company’s strategic situation. The technique is based on the assumption that an effective strategy derives from a sound “fit” between a firm’s internal resources (strengths and weaknesses) and its external situation (opportunities and threats). A good fit maximizes a firm’s strengths and opportunities and minimizes its weaknesses and threats. Accurately applied, this simple assumption has powerful implications for the design of a successful strategy.”

Astrazeneca PLC

AstraZeneca is the second largest pharmaceutical company in the UK. The company was formed in 1999 by the merger of Swedish-based Astra and UK-based Zeneca Group. AstraZeneca has a strong presence in the US and retains a significant presence in Sweden as a legacy of Astra. The company is headquartered in London and employed about 65,000 people.

Strengths, Weaknesses, Opportunities and Threats (SWOT)

Location of Factor

TYPE OF FACTOR

Favorable

Unfavorable

Internal

Strengths

  • Robust Crestor and Symbicort product franchises
  • Strong track record in differentiating key brands/blockbusters from ‘me too’ competitors
  • Strong position in RoW/emerging markets

Weaknesses

  • Over reliance on blockbuster-driven strategy
  • Late stage R&D pipeline adversely impacted by product discontinuations
  • High dependence on small molecule product base

External

Opportunities

  • MedImmune/CAT acquisitions and movement into biologics market
  • Cost-restructuring initiatives
  • Potential in-licensing/co-development opportunities
  • Movement into biosimilars market
  • Extraction of further sales growth in RoW markets

Threats

  • Exposure to generic competition across portfolio of key brands, intensifying from 2011 onwards
underline
About YouSigma Please Donate Using PayPal, to help us Develop Content
Copyright and Disclaimer
Loading
underline
underline
Try a free sample Destiny Reading! Executive Openings! $80,000 to $500,000+
"Astrazeneca PLC (SWOT Analysis)";